Melphalan Zentiva

Melphalan, the active ingredient in Melphalan Zentiva, is an alkylating agent presented as an intravenous formulation for infusion use. It is employed in the treatment of certain hematologic malignancies and solid tumors, including multiple myeloma, ovarian cancer, and melanoma, in adult patients.

GNH USA supplies Melphalan Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies, and clinics worldwide, adhering to EU quality standards and multiple regulatory jurisdictions. The company emphasizes reliable cold‑chain logistics and on‑time delivery to meet the needs of oncology treatment programs.

Melphalan is an alkylating chemotherapy agent used in the management of certain cancers. - Multiple Myeloma: administered as part of conditioning regimens or combination therapy to achieve disease control and extend progression‑free survival. - Ovarian Cancer: incorporated into multi‑agent chemotherapy protocols to enhance tumor shrinkage and improve overall response in advanced or recurrent disease. - Melanoma: used in high‑dose intravenous schedules, often with autologous stem‑cell support, to target metastatic lesions and increase remission rates. - Other Hematologic Malignancies: may be utilized in clinical protocols for select leukemias and lymphomas where alkylating agents are indicated, contributing to cytoreduction.

Melphalan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported during infusion. - Myelosuppression: decreased white blood cells, red cells, and platelets. - Fatigue: generalized tiredness affecting daily activities. - Mucositis: inflammation and ulceration of the oral mucosa. - Hair loss: temporary alopecia may occur during treatment. - Diarrhea: loose stools may develop, requiring hydration.

Serious or Rare Side Effects: - Secondary malignancies: risk of therapy‑related leukemias or solid tumors. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Severe infection: due to profound neutropenia and immunosuppression. - Cardiotoxicity: rare cardiac arrhythmias or reduced left ventricular function. - Renal toxicity: possible acute kidney injury, especially with high doses.

When using Melphalan, clinicians should observe several precautionary measures to minimize risks. - Baseline assessment: obtain complete blood count and organ function tests before initiating therapy. - Monitoring: perform regular hematologic and renal monitoring during treatment cycles. - Dose adjustments: modify dose in patients with impaired hepatic or renal function as per clinical guidelines. - Concomitant medications: avoid concurrent use of other myelosuppressive agents unless medically justified. - Pregnancy and lactation: contraindicated in pregnancy; advise effective contraception and avoid breastfeeding. - Store at ambient temperature: keep vials in original packaging, protect from light and moisture, and store below 25°C.

Melphalan can interact with other agents, influencing its efficacy or toxicity profile.

Major Interactions (Avoid): - Live vaccines: administration may lead to severe infection due to immunosuppression. - Strong CYP inducers: agents that markedly increase hepatic metabolism may reduce melphalan exposure (e.g., rifampin).

Moderate Interactions (Monitor Closely): - Myelosuppressive drugs: concurrent use can exacerbate bone‑marrow suppression (e.g., cyclophosphamide, methotrexate). - Anticoagulants: increased risk of bleeding due to thrombocytopenia. - Nephrotoxic agents: combined use may worsen renal impairment (e.g., cisplatin, NSAIDs).